QuidelOrtho Corporation
QDEL Small CapHealthcare · Medical Devices
Updated: Jun 14, 2026, 22:19 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments a
QuidelOrtho Corporation Stock at a Glance
QuidelOrtho Corporation (QDEL) is currently trading at $14.13 with a market capitalization of $963.5M. The 52-week range spans from $9.92 to $35.58; the current price is 60.3% below the yearly high. Year-over-year revenue growth stands at -10.5%.
💰 Dividend
QuidelOrtho Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
4 analysts rate QuidelOrtho Corporation (QDEL) on consensus: None. The average price target is $18.62, implying +31.81% from the current price. Analyst price targets range from $11.00 to $38.00.
QuidelOrtho Corporation: The Investment Case in Detail
QuidelOrtho Corporation (QDEL) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bear Case
Revenue is contracting at -10.5% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 24.1% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valuation in Context
The EV/EBITDA multiple of 7.52x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.
What to Watch Next
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 31.81% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- Positive free cash flow
- –Revenue shrinking (-10.5% YoY)
- –Currently unprofitable
- –High leverage (D/E 155.27)
- –High short interest (24.1%)
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to relatively defensive market behavior, elevated short interest (24.1%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy QuidelOrtho Corporation?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news